| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/09/2011 | EP2280712A2 Fluocinolone formulations in a biodegradable polymer carrier |
| 02/09/2011 | EP2280711A1 Methods, dosage forms, and kits for administering ziprasidone without food |
| 02/09/2011 | EP2280710A2 Novel treatment of heart diseases |
| 02/09/2011 | EP2280709A1 Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin |
| 02/09/2011 | EP2280708A1 Mmp-2 and/or mmp-9 inhibitor |
| 02/09/2011 | EP2280707A1 Alpha2b and alpha2c agonists |
| 02/09/2011 | EP2280706A1 Lipoprotein lipase-activating compositions comprising benzene derivates |
| 02/09/2011 | EP2280704A1 Oxymethylene aryl compounds and uses thereof |
| 02/09/2011 | EP2280703A1 Use of npy y5 receptor antagonists for the prevention of psychostimulant and opioid abuse |
| 02/09/2011 | EP2280702A2 Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood |
| 02/09/2011 | EP2280701A2 Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
| 02/09/2011 | EP2280700A2 Combination of dronedarone with at least one diuretic, and therapeutic use thereof |
| 02/09/2011 | EP2280699A1 Novel estrogen receptor ligands |
| 02/09/2011 | EP2280698A1 Method for inhibiting the growth of bacteria |
| 02/09/2011 | EP2280697A1 Oral liquid compositions of rhein or diacerein |
| 02/09/2011 | EP2280696A1 Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto |
| 02/09/2011 | EP2280695A1 Hydroxytyrosol benefits mitochondria |
| 02/09/2011 | EP2280694A1 Humidity-resistant drug formulations and methods of preparation thereof |
| 02/09/2011 | EP2280692A1 Tablet comprising eprosartan mesylate |
| 02/09/2011 | EP2280689A1 Stable ophthalmic formulations |
| 02/09/2011 | EP2280688A1 Aqueous pharmaceutical formulation |
| 02/09/2011 | EP2280687A1 Chewing gum compositions comprising cannabinoids |
| 02/09/2011 | EP2280601A2 Amino acid inhibitors of cytochrome p450 |
| 02/09/2011 | EP2083824B1 Methods for treating inflammatory conditions |
| 02/09/2011 | EP2033637B1 Therapeutic or prophylactic agent for leukemia |
| 02/09/2011 | EP1965797B1 Reduction of dizziness, a side effect associated with pirfenidone therapy |
| 02/09/2011 | EP1943251B1 A1 adenosine receptor agonists |
| 02/09/2011 | EP1931656B1 Novel drugs for dementia |
| 02/09/2011 | EP1924579B1 Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives |
| 02/09/2011 | EP1883451B9 Substituted indole compounds having nos inhibitory activity |
| 02/09/2011 | EP1838303B1 Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associates conditions |
| 02/09/2011 | EP1819227B1 Pharmaceutical formulation of decitabine |
| 02/09/2011 | EP1807090B1 Process for the preparation of ibandronate |
| 02/09/2011 | EP1773353B1 Formulations for parenteral administration of (e)-2,6-dialkoxystryryl 4-substituted benzylsulfones |
| 02/09/2011 | EP1750808B1 Myricitrin compounds for treating sleeping disorders |
| 02/09/2011 | EP1689715B1 Tubulin inhibitors |
| 02/09/2011 | EP1689390B1 Methods and reagents for the treatment of inflammatory disorders |
| 02/09/2011 | EP1685100B1 Novel 1, 3-disubstituted azetidine derivatives for use as 5ht2a receptor ligands |
| 02/09/2011 | EP1664005B1 Thiazole derivatives as cannabinoid receptor modulators |
| 02/09/2011 | EP1654224B1 Substituted benzoylureido-o-benzoylamides, method for the production thereof and use of the same |
| 02/09/2011 | EP1644321B1 New benzamides as ppaty modulators |
| 02/09/2011 | EP1575955B1 Pyrrolobenzodiazepines for the treatment of proliferative diseases |
| 02/09/2011 | EP1559426B1 Percutaneous absorption preparations containing 3-methyl-1-phenyl-2-pyrazolin-5-one |
| 02/09/2011 | EP1487825B1 Processes for the preparation of synthetic derivatives of dibenzylbutyrolactonic lignans having anti-chagas properties |
| 02/09/2011 | EP1451192B1 Novel crystalline compound |
| 02/09/2011 | EP1405638B1 Pharmaceutical composition comprising quinuclidin-3'-yl 1-phenyl-1,2,3,4,-tetrahydroisoquinoline-2-carboxylate for treatment of interstitial cystitis and/or abacterial prostatitis |
| 02/09/2011 | EP1379508B9 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof |
| 02/09/2011 | EP1370276B1 Intercellular communication facilitating compounds and their medical use |
| 02/09/2011 | EP1280898B1 Modified es cells and es cell-specific gene |
| 02/09/2011 | EP1011686B9 Modulation of human mast cell activation |
| 02/09/2011 | EP0848755B2 Vegf-related protein |
| 02/09/2011 | CN1985873B Medicine composition of glycyrrhizic acid or its salt, ginseng and astragalus root |
| 02/09/2011 | CN1984901B Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors. |
| 02/09/2011 | CN1977887B Medicinal composition for treating hepatitis |
| 02/09/2011 | CN1961859B Novel formulation of Tizanidine and derivative thereof and preparation method thereof |
| 02/09/2011 | CN1960716B Oral preparations and process for production thereof |
| 02/09/2011 | CN1953753B Crystalline polymorphic forms of monosodium N-[8-(2-hydroxybenzoyl)amino]caprylate |
| 02/09/2011 | CN1951449B Medicament for increasing peripheral blood leukocyte and use thereof |
| 02/09/2011 | CN1889950B The use of urocanic acid being able to acidify the cell cytoplasm and for preventing or halting cellular proliferation in a person |
| 02/09/2011 | CN1889937B Glycopegylated factor IX |
| 02/09/2011 | CN1883603B Compound Chinese medicinal preparation for treating toothache and method for preparing same |
| 02/09/2011 | CN1882602B The modulation of hyaluronan synthesis and degradation in the treatment of disease |
| 02/09/2011 | CN1829496B Use of spermine and/or spermidine against skin ageting in dietary, pharmaceutical or cosmetic compositions |
| 02/09/2011 | CN1812798B Use of hyaluronic acid for preparing compositions for treating oral cavity aphthas |
| 02/09/2011 | CN1799631B Animal model for fetal alcohol syndrome and methods of treatment |
| 02/09/2011 | CN1732955B Pharmaceutical composition making anemarrhena total sapogenin as active ingredient, its preparation method and use |
| 02/09/2011 | CN1726914B Slow release tablet of rotundine and production process |
| 02/09/2011 | CN1547464B Prolonged release bioadhesive therapeutic systems |
| 02/09/2011 | CN101970662A Use of oligonucleotides with modified bases as antiviral agents |
| 02/09/2011 | CN101970473A Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression |
| 02/09/2011 | CN101970460A Functional lipid constructs |
| 02/09/2011 | CN101970452A C20-c21 substituted glucocorticoid receptor agonists |
| 02/09/2011 | CN101970445A Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors |
| 02/09/2011 | CN101970442A Bicyclic pyrrole compound |
| 02/09/2011 | CN101970441A Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors |
| 02/09/2011 | CN101970440A 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| 02/09/2011 | CN101970439A Folates, compositions and uses thereof |
| 02/09/2011 | CN101970438A Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use |
| 02/09/2011 | CN101970437A Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals |
| 02/09/2011 | CN101970436A Azaindole compounds for treatment of central nervous system disorders |
| 02/09/2011 | CN101970433A Gamma secretase modulators |
| 02/09/2011 | CN101970431A Substituted piperidines as therapeutic compounds |
| 02/09/2011 | CN101970430A Novel pyrimidine derivatives |
| 02/09/2011 | CN101970429A 2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace) |
| 02/09/2011 | CN101970428A Carboxamide compounds and their use as calpain inhibitors |
| 02/09/2011 | CN101970426A Indazolyl, benzimidazolyl, benzotriazolyl substituted indolmone derivatives as kinase inhibitors useful in the treatment of cancer |
| 02/09/2011 | CN101970425A Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts |
| 02/09/2011 | CN101970424A Indolyl- pyridone derivatives having checkpoint kinase 1 inhibitory activity |
| 02/09/2011 | CN101970422A Polymorphic form of rotigotine |
| 02/09/2011 | CN101970420A Oxadiazole derivatives |
| 02/09/2011 | CN101970418A Novel compounds, use and preparation thereof |
| 02/09/2011 | CN101970415A 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors |
| 02/09/2011 | CN101970414A 1 ibeta-hydroxysteroid dehydrogenase inhibitors |
| 02/09/2011 | CN101970411A (e) -n -(2-amino-phenyl) -3-{1-[4-(1-methyl-1h-pyrazol-4-yl)- benzenesulfonyl]-1h-pyrrol-3-yl} -acrylamide salts |
| 02/09/2011 | CN101970410A Pyridylaminoacetic acid compound |
| 02/09/2011 | CN101970408A 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine |
| 02/09/2011 | CN101970406A Novel triaryl derivatives useful as modulators of nicotinic acetylcholine receptors |
| 02/09/2011 | CN101970405A Indoles and their therapeutic use |
| 02/09/2011 | CN101970404A Novel method for the production of sulphonylpyrroles as hdac inhibitors |
| 02/09/2011 | CN101970401A Leukotriene b4 inhibitors |